This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration.
The Food and Drug Administration (FDA) is announcing a public workshop, co-sponsored with the Infectious Diseases Society of America (IDSA), regarding scientific issues in the development of molecular and other tests for the diagnosis of respiratory infections, entitled “Advancing Clinical Development of Molecular and Other Diagnostic Tests for Respiratory Tract Infections.” The purpose of the public workshop is to provide an opportunity to share information and perspectives with health care providers, academia, and industry on various aspects of diagnostic test development for respiratory infections. Topics for discussion will include the role of emerging diagnostic tests in promoting appropriate use of antibiotics by physicians, the use of novel diagnostic tests in the study of new drugs for respiratory infections, and the possible contribution of biomarkers in the approach to treatment of respiratory infections.
Date and Time: The public workshop will be held on November 12, 2009, from 8 a.m. to 6 p.m. and on November 13, 2009, from 8 a.m. to 4:30 p.m.
Location: The public workshop will be held at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD 20877. Seating is limited and available only on a first-come, first-served basis.
Contact Person: Christine Kellerman, Center for Devices and Radiological Health, Food and Drug Administration, Office of In Vitro Diagnostic Devices, 10903 New Hampshire Ave., Building 66, rm. 5677, Silver Spring, MD 20993-0002, 301-796-5711.
Registration: To register electronically, e-mail registration information (including: Name, title, firm name, address, telephone, and fax numbers) to Respdiagmtg@fda.hhs.gov by November 8, 2009. Persons without access to the Internet can call 301-796-5711 to register. Registration is free for the public workshop. Interested parties are encouraged to register early because space is limited. Seating will be available on a first-come, first-served basis. Persons needing a sign language interpreter or other special accommodations should notify Christine Kellerman (see Contact Person) at least 7 days in advance. Additional information is also available at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm181140.htm.End Preamble Start Supplemental Information
New diagnostic technologies offer opportunities to guide the appropriate clinical use of anti-infective agents, facilitate the study of new anti-infective agents, and aid in tracking the spread of infectious diseases. To explore issues regarding the development and adoption of emerging diagnostic tests, FDA is announcing a public workshop, co-sponsored with IDSA to address scientific issues in the development of in vitro diagnostic tests for respiratory infections.
II. Topics for Discussion at the Public Workshop
Topics to be discussed at the workshop include:
- Principles of clinical trial design and their application to studies of new diagnostics, or studies where new diagnostics and new drugs are investigated simultaneously;
- Test characteristics for emerging tests that would promote clinical adoption and improve antibiotic stewardship;
- Principles for including specific viral or bacterial pathogens in multiplex diagnostic test panels;
- Discussion of approaches to developing a new molecular method when there is no “gold standard” reference method; and
- The use of biomarkers in respiratory infections.
The input from this public workshop will help in developing topics for further discussion. The agency encourages individuals, patient advocates, industry, consumer groups, health care professionals, researchers, and other interested persons to attend this public workshop.
Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 6-30, Rockville, MD 20857, approximately 20 working days after the public workshop at a cost of 10 cents per page. A link to the transcripts will also be available on the Internet at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm approximately 45 days after the workshop.Start Signature
Dated: October 7, 2009.
Acting Director, Center for Devices and Radiological Health.
[FR Doc. E9-24828 Filed 10-14-09; 8:45 am]
BILLING CODE 4160-01-S